Skip to main content
Clinical Trials/KCT0000526
KCT0000526
Recruiting
未知

An investigator intitiated clnical trial for evaluating the efficacy and safety of 131I-Rituximab treatment as consolidation in the patients with CD20 positive advanced diffuse large B-cell lymphoma after standard combination chemotherapy

ConditionsNeoplasms

Overview

Phase
未知
Intervention
Not specified
Conditions
Neoplasms
Sponsor
Korea Institute of Radiological & Medical Sciences
Enrollment
56
Status
Recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional Study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. hitologically confirmed CD20 positive diffuse large B cell lymphoma
  • 2\. chemo\-naive patient
  • 3\. no previous history of radiation therapy
  • 4\. no previous history of immunotherapy
  • 5\. measurable lesions?? ??? ??? ?? ?
  • 6\. \=20 years old
  • 7\. Eastern Cooperative Oncology Group performance status \= 2
  • 8\. adequate liver, kidney, bone marrow function
  • \- serum creatinine\=1\.5 mg/dl or creatinine clearance \=60 ml/min
  • \- serum transaminases \< 5 x upper normal limit

Exclusion Criteria

  • 1\. patients with involvement of cerebrospinal fluid
  • 2\. primary central nervous system lymphoma or diffuse large B cell lymphoma with central nervous system involvement
  • 3\. HIV positive
  • 4\. recent (\<5 years) history of other malignancy or unrecovered from the disease (appropriately treated skin cancer and uterine cervix carcinoma in situ are excluded)
  • 5\. hemodynamically unstable due to the recent (\<12 months) history of severe heart disease such as myocardial infarction
  • 6\. acute complications of severe lung or metabolic disease
  • 7\. Combined severe neurological or psychiatric disease
  • 8\. Unrecovered from infection or other medical disease
  • 9\. Recent (\<30 days) history of enrollment of other clinical trial
  • 10\. more than 25% of lymphoma marrow involvement

Outcomes

Primary Outcomes

Not specified

Similar Trials